New members join Novartis, Janssen, and Eli Lilly to develop adaptive design and execution methodologies for improved decision-making in exploratory studies.
Quarter 2 net revenue increased 12.5% year on year to $376 million; income from operations was $48.3 million and EPS was 64 cents.
5-day education programme led by key opinion leaders from the pricing and market access industry and academia.
ICON experts will educate attendees on a range of topics, including innovative partnering models and outsourcing strategies, risk-based monitoring, functional service provision, novel adaptive design approaches and clinical outcomes assessment.
Award honours ICONIK’s capabilities for delivering unique clinical study insights
Partnership includes scholarships and participation in GPA’s new mentorship programme
ICON today announced that Aptiv Solutions, an ICON plc company leading the design and implementation of adaptive trials, has released ADDPLAN® DF 3.0, which incorporates complex statistical methodologies to prevent under and over- estimation of a therapeutic’s maximum target dose (MTD) during Phase I dose escalation trials.
ICON today announced the appointment of Dr. Hugh Brady as a non-executive director
ICON today reported its financial results for the first quarter ended March 31, 2014. For the first quarter, net revenue grew 10% year on year to $349.6 million from $316.8 million in Q1 2013.